France 2030: an ambitious plan awaiting its instructions for use
Emmanuel Macron presented the multiple projects financed by the "France 2030" program, which provides a 30 billion euro envelope to develop future technologies. Companies are waiting to hear more about how the funds will be distributed.
The goal is to "build the France of 2030" and "bring out the champions of tomorrow in our country and in Europe". Emmanuel Macron unveiled his €30 billion France 2030 plan on Tuesday, October 12, 2021, and detailed the list of sectors covered by this new program.
So who will really benefit from this plan? About ten sectors are concerned. First, the President wants to invest one billion euros in nuclear energy and develop innovative small nuclear reactors in France by 2030, with innovative waste management.
The second issue is hydrogen. The goal is to become the leader in green hydrogen by 2030 and to produce "at least two gigafactories or electrolysers by 2030.
4 billion for the transportation of the future
The President's third objective is to decarbonize industry. The government is committed to reducing emissions in the industrial sector by 35% between 2015 and 2030. "Today, in 2021, we have made 4%, so we must invest massively. Without public investment, it is unsustainable," said Emmanuel Macron.
Other sectors supported: automotive and aerospace. Nearly 4 billion euros will be allocated to these two industries. The government has set itself the goal of producing nearly 2 million electric and hybrid vehicles and building the first low-carbon aircraft.
Supporting health and electronic components
Emmanuel Macron also wants to "invest in healthy, sustainable and traceable food" and "accelerate the agricultural and agri-food revolution". In this area, 2 billion euros are planned in digital technologies, robotics and genetics.
The France 2030 plan also provides for a 3 billion euro envelope in the field of health "to regain the lead on a more predictive medicine," as well as an investment of nearly 6 billion euros to double the production of electronic components in France, while shortages of semiconductors affect the entire global industry. Europe now produces only 2% of the world's electronic components," lamented the President. Yet, more and more, everything is robotic and electronic. We need to secure all these components. "
Cuong Duong, CEO of Linxens, an ETI specializing in the manufacture of micro-connectors, should be among the companies affected by the aid. "This plan, even if it is not yet clear and transparent enough for us to move forward, will encourage companies to invest in France," says the CEO. Linxens has operations in six countries (France, Germany, India, Singapore, Thailand and China).
With a few tens of millions of euros of aid, the company, which employs 350 people in France, could expand, open new factories in France and create many jobs. The company plans to develop a biometric smart card center in Mantes-la-Jolie in the Yvelines and to create a medical facility in the same factory. "We are going to continue to accelerate innovations in terms of health by developing intelligent dressings and hire more R&D profiles to work on new generations of micro-connector products," reports Cuong Duong.
Favoring Made In France companies
Another possible beneficiary of the aid (at least on paper) is Pierre-Edouard Saillard, CEO and co-founder of Archeon. His company markets medical devices based on artificial intelligence for emergency medicine and first aid. If his business sector is eligible for the announced support, the actual terms and conditions are still to be determined. "We are waiting for the opening of the calls for projects to know more. It's still relatively vague," confirms the head of the 16-employee company, which achieved a turnover of 300,000 euros in 2020. With this aid, Pierre-Edouard Saillard wants to finance new projects, but also create a dozen jobs by 2022 to strengthen the marketing team, engineering, and increase market penetration internationally. Part of the funds will also be dedicated to clinical trials.